Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis.

Volume: 146, Issue: 1, Pages: 96 - 109
Published: Jan 1, 2014
Abstract
Background & Aims null Subcutaneous golimumab, a fully human monoclonal antibody to tumor necrosis factor-α (TNFα), was evaluated as maintenance therapy in TNFα antagonist-naive adults with moderate-to-severe active ulcerative colitis, despite conventional therapy, who responded to golimumab induction therapy. null Methods null We performed a phase 3, double-blind trial of patients who completed golimumab induction trials (Program of Ulcerative...
Paper Fields
Paper Details
Title
Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis.
Published Date
Jan 1, 2014
Volume
146
Issue
1
Pages
96 - 109
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.